{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:41:06Z","timestamp":1780584066889,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with hematological malignancies (HMs) are at a higher risk of developing severe form and protracted course of COVID-19 disease. We investigated whether the combination of viral replication inhibition with remdesivir and administration of anti-SARS-CoV-2 immunoglobulins with convalescent plasma (CP) therapy might be sufficient to treat B-cell-depleted patients with COVID-19. We enrolled 20 consecutive patients with various HMs with profound B-cell lymphopenia and COVID-19 pneumonia between December 2020 and May 2021. All patients demonstrated undetectable baseline anti-SARS-CoV-2 immunoglobulin levels before CP. Each patient received at least a complete course of remdesivir and at least one unit of CP. Previous anti-CD20 therapy resulted in a more prolonged SARS-CoV-2 PCR positivity compared to other causes of B-cell lymphopenia (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). Timing of CP therapy showed a significant impact on the clinical outcome. Simultaneous use of remdesivir and CP reduced time period for oxygen weaning after diagnosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.017), length of hospital stay (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), and PCR positivity (<jats:italic>p<\/jats:italic>\u2009=\u20090.012) compared to patients who received remdesivir and CP consecutively. In addition, time from the diagnosis to CP therapy affected the length of oxygen dependency (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and hospital stay (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In those cases where there were at least 10\u00a0days from the diagnosis to plasma administration, oxygen dependency was prolonged vs. patients with shorter interval (<jats:italic>p<\/jats:italic>\u2009=\u20090.006). In conclusion, the combination of inhibition of viral replication with passive immunization was proved to be efficient and safe. Our results suggest the clear benefit of early, combined administration of remdesivir and CP to avoid protracted COVID-19 disease among patients with HMs and B-cell lymphopenia.<\/jats:p>","DOI":"10.1007\/s00277-022-04924-6","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T20:03:40Z","timestamp":1657829020000},"page":"2337-2345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies"],"prefix":"10.1007","volume":"101","author":[{"given":"Ferenc","family":"Magyari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-1709","authenticated-orcid":false,"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"P\u00e1yer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Ujfalusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Di\u00f3szegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1t\u00e9","family":"Sik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Hevessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"B\u00e9la","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"4924_CR1","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/BLOOD.2020008423","volume":"136","author":"T Hueso","year":"2020","unstructured":"Hueso T, Pouderoux C, P\u00e9r\u00e9 H et al (2020) Convalescent plasma therapy for B-cell\u2013depleted patients with protracted COVID-19. Blood 136:2290\u20132295. https:\/\/doi.org\/10.1182\/BLOOD.2020008423","journal-title":"Blood"},{"key":"4924_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F et al (2021) COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 14:168. https:\/\/doi.org\/10.1186\/s13045-021-01177-0","journal-title":"J Hematol Oncol"},{"key":"4924_CR3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/AJH.26209","volume":"96","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Lamure S, Delord M et al (2021) Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol 96:934\u2013944. https:\/\/doi.org\/10.1002\/AJH.26209","journal-title":"Am J Hematol"},{"key":"4924_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2217\/IMT-2017-0178","volume":"10","author":"KA Sacco","year":"2018","unstructured":"Sacco KA, Abraham RS (2018) Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy 10:713\u2013728. https:\/\/doi.org\/10.2217\/IMT-2017-0178","journal-title":"Immunotherapy"},{"key":"4924_CR5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/nejmoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of Covid-19 \u2014 Final Report. N Engl J Med 383:1813\u20131826. https:\/\/doi.org\/10.1056\/nejmoa2007764","journal-title":"N Engl J Med"},{"key":"4924_CR6","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","volume":"11","author":"MS Buckland","year":"2020","unstructured":"Buckland MS, Galloway JB, Fhogartaigh CN et al (2020) Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun 11:6385. https:\/\/doi.org\/10.1038\/s41467-020-19761-2","journal-title":"Nat Commun"},{"key":"4924_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","volume":"190","author":"PR Tepasse","year":"2020","unstructured":"Tepasse PR, Hafezi W, Lutz M et al (2020) Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 190:185\u2013188. https:\/\/doi.org\/10.1111\/bjh.16896","journal-title":"Br J Haematol"},{"key":"4924_CR8","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1097\/HS9.0000000000000603","volume":"5","author":"E Gaitzsch","year":"2021","unstructured":"Gaitzsch E, Passerini V, Khatamzas E et al (2021) COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma. HemaSphere 5:e603. https:\/\/doi.org\/10.1097\/HS9.0000000000000603","journal-title":"HemaSphere"},{"key":"4924_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani O, Abbas A, Abbas F et al (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397:2049\u20132059. https:\/\/doi.org\/10.1016\/S0140-6736(21)00897-7","journal-title":"Lancet"},{"key":"4924_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/S10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng Y, Wong R, Soo YOY et al (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44\u201346. https:\/\/doi.org\/10.1007\/S10096-004-1271-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4924_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"JH Ko","year":"2018","unstructured":"Ko JH, Seok H, Cho SY et al (2018) Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 23:617\u2013622. https:\/\/doi.org\/10.3851\/IMP3243","journal-title":"Antivir Ther"},{"key":"4924_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA, Burgos Pratx LD, Scibona P et al (2021) A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 384:619\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2031304","journal-title":"N Engl J Med"},{"key":"4924_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/JAMAONCOL.2021.1799","volume":"7","author":"MA Thompson","year":"2021","unstructured":"Thompson MA, Henderson JP, Shah PK et al (2021) Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol 7:1167\u20131175. https:\/\/doi.org\/10.1001\/JAMAONCOL.2021.1799","journal-title":"JAMA Oncol"},{"key":"4924_CR14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","volume":"36","author":"T Hueso","year":"2022","unstructured":"Hueso T, Godron A-S, Lanoy E et al (2022) Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia 36:1025\u20131034. https:\/\/doi.org\/10.1038\/s41375-022-01511-6","journal-title":"Leukemia"},{"key":"4924_CR15","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"JC Marshall","year":"2020","unstructured":"Marshall JC, Murthy S, Diaz J et al (2020) A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 20:e192\u2013e197. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7","journal-title":"Lancet Infect Dis"},{"key":"4924_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-020-00968-1","volume":"13","author":"G Lancman","year":"2020","unstructured":"Lancman G, Mascarenhas J, Bar-Natan M (2020) Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 13:131. https:\/\/doi.org\/10.1186\/s13045-020-00968-1","journal-title":"J Hematol Oncol"},{"key":"4924_CR17","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/bjh.16981","volume":"190","author":"E Clark","year":"2020","unstructured":"Clark E, Guilpain P, Filip IL et al (2020) Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol 190:e154\u2013e156. https:\/\/doi.org\/10.1111\/bjh.16981","journal-title":"Br J Haematol"},{"key":"4924_CR18","doi-asserted-by":"publisher","first-page":"108723","DOI":"10.1016\/J.CLIM.2021.108723","volume":"227","author":"A Kenig","year":"2021","unstructured":"Kenig A, Ishay Y, Kharouf F, Rubin L (2021) Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol 227:108723. https:\/\/doi.org\/10.1016\/J.CLIM.2021.108723","journal-title":"Clin Immunol"},{"key":"4924_CR19","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clml.2021.05.013","volume":"21","author":"A Furlan","year":"2021","unstructured":"Furlan A, Forner G, Cipriani L et al (2021) Dramatic response to convalescent hyperimmune plasma in association with an extended course of remdesivir in 4 B cell\u2013depleted non-Hodgkin lymphoma patients with SARS-Cov-2 pneumonia After Rituximab Therapy. Clin Lymphoma Myeloma Leuk 21:e731\u2013e735. https:\/\/doi.org\/10.1016\/j.clml.2021.05.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4924_CR20","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","volume":"62","author":"S Ferrari","year":"2021","unstructured":"Ferrari S, Caprioli C, Weber A et al (2021) Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 62:1490\u20131496. https:\/\/doi.org\/10.1080\/10428194.2021.1872070","journal-title":"Leuk Lymphoma"},{"key":"4924_CR21","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/J.CLINPR.2021.100096","volume":"12","author":"G Casarola","year":"2021","unstructured":"Casarola G, D\u2019Abbondanza M, Curcio R et al (2021) Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: a case report. Clin Infect Pract 12:100096. https:\/\/doi.org\/10.1016\/J.CLINPR.2021.100096","journal-title":"Clin Infect Pract"},{"key":"4924_CR22","doi-asserted-by":"publisher","first-page":"e4020","DOI":"10.1093\/cid\/ciaa1637","volume":"73","author":"J Malsy","year":"2021","unstructured":"Malsy J, Veletzky L, Heide J et al (2021) Sustained response after remdesivir and convalescent plasma therapy in a B-cell\u2013depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin Infect Dis 73:e4020\u2013e4024. https:\/\/doi.org\/10.1093\/cid\/ciaa1637","journal-title":"Clin Infect Dis"},{"key":"4924_CR23","doi-asserted-by":"publisher","unstructured":"Nussenblatt V, Roder AE, Das S et al (2021) Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. J Infect Dis:jiab622. https:\/\/doi.org\/10.1093\/INFDIS\/JIAB622","DOI":"10.1093\/INFDIS\/JIAB622"},{"key":"4924_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/HON.2908","volume":"39","author":"B Weinbergerova","year":"2021","unstructured":"Weinbergerova B, Mayer J, Kabut T et al (2021) Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. Hematol Oncol 39:715\u2013720. https:\/\/doi.org\/10.1002\/HON.2908","journal-title":"Hematol Oncol"},{"key":"4924_CR25","doi-asserted-by":"publisher","first-page":"ofab391","DOI":"10.1093\/OFID\/OFAB391","volume":"8","author":"J Koirala","year":"2021","unstructured":"Koirala J, Gyanwali P, Gerzoff RB et al (2021) Experience of Treating COVID-19 with remdesivir and convalescent plasma in a resource-limited setting: a prospective, observational study. Open Forum Infect Dis 8:ofab391. https:\/\/doi.org\/10.1093\/OFID\/OFAB391","journal-title":"Open Forum Infect Dis"},{"key":"4924_CR26","doi-asserted-by":"publisher","unstructured":"Gharbharan A, Geurts van Kessel CH, Jordans CCE et al (2021) Effects of treatment of coronavirus disease 2019 with convalescent plasma in 25 B-cell\u2013depleted patients. Clin Infect Dis:ciab647. https:\/\/doi.org\/10.1093\/CID\/CIAB647","DOI":"10.1093\/CID\/CIAB647"},{"key":"4924_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1556\/2068.2020.53.2.6","volume":"53","author":"A Tordai","year":"2020","unstructured":"Tordai A, Nagy S, Bar\u00f3ti-T\u00f3th K et al (2020) Effect of the SARS-CoV2 pandemic in Hungarian blood banking. Hematol\u00f3gia\u2013Transzfuziol\u00f3gia 53:96\u2013105. https:\/\/doi.org\/10.1556\/2068.2020.53.2.6","journal-title":"Hematol\u00f3gia\u2013Transzfuziol\u00f3gia"},{"key":"4924_CR28","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo FJ, Fulcher JA, Goodman-Meza D et al (2020) Rapid decay of anti\u2013SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 383:1085\u20131087. https:\/\/doi.org\/10.1056\/NEJMc2025179","journal-title":"N Engl J Med"},{"key":"4924_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.17806","author":"C Schenker","year":"2021","unstructured":"Schenker C, Hirzel C, Walti LN et al (2021) Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response. Br J Haematol. https:\/\/doi.org\/10.1111\/BJH.17806","journal-title":"Br J Haematol"},{"key":"4924_CR30","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1016\/S2666-5247(21)00030-6","volume":"2","author":"RN Rodionov","year":"2021","unstructured":"Rodionov RN, Biener A, Spieth P et al (2021) Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe 2:e138. https:\/\/doi.org\/10.1016\/S2666-5247(21)00030-6","journal-title":"Lancet Microbe"},{"key":"4924_CR31","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/BLOOD.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136:2881\u20132892. https:\/\/doi.org\/10.1182\/BLOOD.2020008824","journal-title":"Blood"},{"key":"4924_CR32","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1016\/J.CRWH.2020.E00221","volume":"27","author":"J Anderson","year":"2020","unstructured":"Anderson J, Schauer J, Bryant S, Graves CR (2020) The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Rep Womens Health 27:e00221. https:\/\/doi.org\/10.1016\/J.CRWH.2020.E00221","journal-title":"Case Rep Womens Health"},{"key":"4924_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.23937\/2378-3656\/1410349","volume":"8","author":"E Ahmed","year":"2021","unstructured":"Ahmed E, Dina E, Usman A (2021) The effect of remdesivir and convalescent plasma in severe COVID-19 in pregnancy. Clin Med Rev Case Rep 8:349. https:\/\/doi.org\/10.23937\/2378-3656\/1410349","journal-title":"Clin Med Rev Case Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04924-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:06:18Z","timestamp":1662703578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04924-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4924"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04924-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Scientific and Research Ethics Committee of the University of Debrecen and the Ministry of Human Capacities under the registration number of 32568\u20133\/2020\/E\u00dcIG. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}